ENTYVIO Sales Forecast, and Market Size Analysis - 2034

Key Factors Driving ENTYVIO Growth

1. Consistent Blockbuster Sales Growth

ENTYVIO remains one of Takeda's top growth brands. Takeda reported FY2023/24 ENTYVIO sales of approximately ¥746 billion (~US$5 billion) globally, reflecting continued double-digit operational growth in several regions. Quarterly reports during FY2024 highlighted growth rates of approximately 13-17% year-over-year in major markets.

Takeda continues to position ENTYVIO as a key long-term growth driver as legacy products lose exclusivity.

2. Expansion of Subcutaneous (SC) Formulation

A major catalyst has been the FDA approval of subcutaneous ENTYVIO Pen for both UC and Crohn's disease maintenance therapy. The SC formulation allows patients to self-administer treatment at home every two weeks, reducing infusion-center dependence and improving convenience.

In the pivotal VISIBLE 2 trial for Crohn's disease:

• 48% of patients on ENTYVIO SC achieved clinical remission at Week 52 versus 34% on placebo.

The SC transition is expected to improve patient retention and broaden physician adoption globally.

3. Strong Positioning in the Expanding IBD Market

ENTYVIO is approved for:

• Moderately-to-severely active ulcerative colitis
• Moderately-to-severely active Crohn's disease

Global IBD prevalence continues to rise, particularly in North America, Europe, and increasingly in Asia-Pacific regions. Growing diagnosis rates and earlier biologic use are supporting sustained demand for advanced therapies such as vedolizumab.

4. Differentiated Gut-Selective Mechanism with Favorable Safety Profile

ENTYVIO specifically targets the a4B7 integrin pathway in the gastrointestinal tract, reducing gut inflammation while limiting systemic immunosuppression.

This gut-selective mechanism has become a major competitive advantage, especially for patients and physicians concerned about infection risks associated with systemic immunosuppressive biologics and JAK inhibitors. The favorable long-term safety profile has strengthened its use as both earlier-line and maintenance therapy.

5. Growing Real-World Physician and Patient Confidence

Long-term remission durability and tolerability continue to drive adoption in clinical practice. Real-world physician experience and patient-reported outcomes have reinforced confidence in ENTYVIO, especially among biologic-experienced patients.

ENTYVIO Recent Developments

• In February 2026, Takeda announced positive results from the Phase III KEPLER trial, demonstrating vedolizumab's efficacy and safety profile in achieving clinical remission for patients ages 2 and older with moderately to severely active UC.

"ENTYVIO Sales Forecast, and Market Size Analysis - 2034" report provides comprehensive insights of ENTYVIO for approved indication like Crohn's disease, Pouchitis and Ulcerative colitis; as well as potential indication like Graft-versus-host disease and Coeliac disease in the 7MM. A detailed picture of ENTYVIO's existing usage in approved and anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 -2034 is provided in this report along with a detailed description of the ENTYVIO for approved and potential indications. The ENTYVIO market report provides insights about ENTYVIO's sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current ENTYVIO performance, future market assessments inclusive of the ENTYVIO market forecast analysis for approved and potential indications in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of ENTYVIO sales forecasts, along with factors driving its market.

ENTYVIO Drug Summary

ENTYVIO is a gut-selective biologic therapy developed by Takeda Pharmaceutical Company for the treatment of moderately to severely active ulcerative colitis and Crohn's disease in adults. It is a humanized monoclonal antibody that specifically targets the a4B7 integrin on lymphocytes, blocking their interaction with MAdCAM-1 and thereby preventing inflammatory immune cells from migrating into gastrointestinal tissue, which helps reduce chronic gut inflammation while minimizing systemic immunosuppression. ENTYVIO is available as both intravenous infusion and subcutaneous injection formulations, offering flexible maintenance therapy options for patients with inflammatory bowel disease (IBD). Approved initially in 2014, the drug has demonstrated strong efficacy in inducing and maintaining clinical remission through pivotal GEMINI studies and is recognized for its favorable safety profile compared with broader immunosuppressive biologics, particularly due to its gut-selective mechanism. Common adverse events include headache, nasopharyngitis, arthralgia, nausea, and upper respiratory infections, while patients are also monitored for infection risk and hypersensitivity reactions during therapy. The report provides ENTYVIO's sales, growth barriers and drivers, post usage and approvals in multiple indications.

Scope of the ENTYVIO Market Report

The report provides insights into:

• A comprehensive product overview including the ENTYVIO MoA, description, dosage and administration, research and development activities in approved indications like Crohn's disease, Pouchitis and Ulcerative colitis; as well as potential indication like Graft-versus-host disease and Coeliac disease.
• Elaborated details on ENTYVIO regulatory milestones and other development activities have been provided in ENTYVIO market report.
• The report also highlights ENTYVIO's cost estimates and regional variations, reported and estimated sales performance, research and development activities in approved and potential indications across the United States, Europe, and Japan.
• The ENTYVIO market report also covers the patents information, generic entry and impact on cost cut.
• The ENTYVIO market report contains current and forecasted ENTYVIO sales for approved and potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The ENTYVIO market report also features the SWOT analysis with analyst views for ENTYVIO in approved and potential indications.

Methodology:

The ENTYVIO market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

ENTYVIO Analytical Perspective by DelveInsight

• In-depth ENTYVIO Market Assessment

This ENTYVIO sales market forecast report provides a detailed market assessment of ENTYVIO for approved indication like Crohn's disease, Pouchitis and Ulcerative colitis; as well as potential indication like Graft-versus-host disease and Coeliac disease in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted ENTYVIO sales data uptil 2034.

• ENTYVIO Clinical Assessment

The ENTYVIO market report provides the clinical trials information of ENTYVIO for approved and potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

ENTYVIO Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

ENTYVIO Market Potential & Revenue Forecast

• Projected market size for the ENTYVIO and its key indications
• Estimated ENTYVIO sales potential (ENTYVIO peak sales forecasts)
• ENTYVIO Pricing strategies and reimbursement landscape

ENTYVIO Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• ENTYVIO Market positioning compared to existing treatments
• ENTYVIO Strengths & weaknesses relative to competitors

ENTYVIO Regulatory & Commercial Milestones

• ENTYVIO Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

ENTYVIO Clinical Differentiation

• ENTYVIO Efficacy & safety advantages over existing drugs
• ENTYVIO Unique selling points

ENTYVIO Market Report Highlights

• In the coming years, the ENTYVIO market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The ENTYVIO companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence ENTYVIO's dominance.
• Other emerging products for Crohn's disease, Pouchitis and Ulcerative colitis; as well as potential indication like Graft-versus-host disease and Coeliac disease are expected to give tough market competition to ENTYVIO and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of ENTYVIO in approved and potential indications.
• Analyse ENTYVIO cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted ENTYVIO sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of ENTYVIO in approved and potential indications.

Key Questions:

• What is the class of therapy, route of administration and mechanism of action of ENTYVIO? How strong is ENTYVIO's clinical and commercial performance?
• What is ENTYVIO's clinical trial status in each individual indications such as Crohn's disease, Pouchitis and Ulcerative colitis; as well as potential indication like Graft-versus-host disease and Coeliac disease and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the ENTYVIO Manufacturers?
• What are the key designations that have been granted to ENTYVIO for approved and potential indications? How are they going to impact ENTYVIO's penetration in various geographies?
• What is the current and forecasted ENTYVIO market scenario for approved and potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of ENTYVIO in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to ENTYVIO for approved and potential indications?
• Which are the late-stage emerging therapies under development for the treatment of approved and potential indications?
• How cost-effective is ENTYVIO? What is the duration of therapy and what are the geographical variations in cost per patient?